Last year at this time, the FDA was beginning to reach into Q1 of 2018 to hurry up a slate of new drug approvals that pushed the agency to a new record high, both a current-generation agency best as well as an overall spike that broke into virgin territory for the first time in 20 years — provided you added a group of major new biologics to the new therapeutics list.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,